What question did this study set out to answer?

The aim is to assess how well the AMAP score predicts 28-day mortality in patients with acute pancreatitis.

February 28, 2026Journal of Medicine and Palliative Care0 citations

Age-male-albumin-bilirubin-platelet (aMAP) score as a predictor of 28-day mortality in acute pancreatitis

BYBetül Çiğdem Yortanlı ABAyşen Bayram BKBurak Kocaoğlu

Key Points

The aim is to assess how well the AMAP score predicts 28-day mortality in patients with acute pancreatitis.
Retrospective analysis of adult patients diagnosed with acute pancreatitis.
Data collected included demographic characteristics, laboratory findings, clinical parameters, and mortality outcomes.
AMAP scores calculated using a validated formula.
Comparison of AMAP score performance against ALBI, BISAP, SOFA, and lactate levels.
Used logistic regression and ROC curve analysis for evaluation.
Included a total of 386 patients for analysis.
Median age significantly higher in non-survivors (77 years) compared to survivors (60 years).
Statistically significant differences in prognostic performance compared to other scores.

Abstract

Aims: This study aimed to evaluate the prognostic performance of the age–male–albumin–bilirubin–platelet (aMAP) score in predicting 28-day mortality among patients with acute pancreatitis (AP) presenting to the emergency department (ED).Methods: We retrospectively analyzed adult patients diagnosed with AP between January 2020 and December 2024 in a tertiary ED. Demographic characteristics, laboratory findings, clinical parameters, and mortality outcomes were recorded. aMAP scores were calculated using a validated formula. The prognostic performance of the aMAP score was compared with that of ALBI, BISAP, SOFA, and lactate levels using logistic regression and ROC curve analysis. Results: A total of 386 patients were included in the analysis. The median age was significantly higher among non-survivors than survivors (77 vs. 60 years, p

KI fragen

Bookmark

View Full Paper